Exploring the potential of novel xanthine oxidase inhibitory peptide (ACECD) derived from Skipjack tuna hydrolysates using affinity-ultrafiltration coupled with HPLC–MALDI-TOF/TOF-MS. (15th June 2021)

• Record Type: Journal Article
• Authors: Zhong, Hao; Abdullah, ; Zhang, Yipeng; Deng, Lingli; Zhao, Minjie; Tang, Jun; Zhang, Hui; Feng, Fengqin; Wang, Jing
• Is Part Of: Food chemistry. Volume 347(2021)
• Publication Date: 2021-06-15
• Subjects: Skipjack tuna -- XOD inhibitory activity -- ACECD peptide -- Affinity-ultrafiltration -- Molecular docking; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; 664
• DOI: 10.1016/j.foodchem.2021.129068
• Languages: English
• ISSNs: 0308-8146

Abstract

Graphical abstract: Highlights: Novelty; affinity-ultrafiltration technique used to explore XODI peptide. Peptides with MW cutoff of 600–1000 Da (UF-2) possessed XODI potential. UF-2 exhibited the highest antioxidant and XODI activities. ACECD discovered as a novel XODI peptide derived from Skipjack tuna. ACECD and UF-2 possibly be used as nutraceuticals for hyperuricemia treatment. Abstract: This study aimed to isolate and investigate the potential of the peptide alanine-cysteine-glutamic acid-cysteine-aspartic acid (ACECD), a novel xanthine oxidase inhibitory (XODI) peptide derived from Skipjack tuna hydrolysate (HS). Ultrafiltration membranes were used to obtain HS-based peptides as successive ultrafiltration fractions (of decreasing molecular weight) of UF-1, UF-2, UF-3, and UF-4. Their antioxidant and xanthine oxidase (XOD) inhibitory activities were determined and further characterized by affinity-ultrafiltration coupled with HPLC-MALDI-TOF/TOF-MS and in silico techniques. The results showed that peptides with a molecular weight (MW) cutoff of 600–1000 Da (UF-2) exhibited the highest antioxidant and XODI activities. A novel XODI peptide (ACECD) was identified with an IC50 value of 13.40 mmol/L, which decreased by 21.24% and 51.40% compared to those of UF-2 and HS, respectively. Molecular docking indicated that ACECD inserted into the active center of Mo atoms in XOD, which led to competitive attachment with XOD and caused inhibition. The study findings indicated that the ACECD peptide could be useful as a safe XODI substance to alleviate hyperuricemia.